Prospective evaluation of qualitative and quantitative 18F-FDG PET-CT parameters for predicting survival in recurrent carcinoma of the cervix

Nuclear Medicine Communications

Volumn 34, Issue 8, 2013, Pages 741-748

  Maharjan, Sagar ^a   Sharma, Punit ^a   Patel, Chetan D ^a   Sharma, Daya N ^a   Dhull, Varun S ^a   Jain, Sunesh K ^a   Thulkar, Sanjay ^a   Malhotra, Arun ^a   Kumar, Rakesh ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

18F fluorodeoxyglucose; Cervical carcinoma; Overall survival; Positron emission tomography computed tomography; Prognosis; Progression free survival; Recurrence

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISTANT METASTASIS; DRUG UPTAKE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GLYCOLYSIS; HISTOLOGY; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; SURVIVAL PREDICTION; UTERINE CERVIX CARCINOMA;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; UTERINE CERVICAL NEOPLASMS;

EID: 84879976311     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283622f0d     Document Type: Article

References (29)

1. Moore MA, Ariyaratne Y, Badar F, Bhurgri Y, Datta K, Mathew A, et al. Cancer epidemiology in South Asia - past, present and future. Asian Pac J Cancer Prev 2010; 11:S49-S66.
2. Waggoner SE. Cervical cancer. Lancet 2003; 361:2217-2225.
3. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomized study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer. Lancet 1997; 350:535-540.
4. Wang CJ, Lai CH, Huang HJ, Hong JH, Chou HH, Huang KG, et al. Recurrent cervical carcinoma after primary radical surgery. Am J Obstet Gynecol 1999; 181:518-524.
5. Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Lee SP, et al. Recurrent squamous cell carcinoma of cervix following definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60:249-257.
6. Eralp Y, Saip P, Sakar B, Kucucuk S, Aydiner A, Dincer M, et al. Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer 2002; 13:497-504.
7. Tabata T, Takeshim N, Tanaka N, Hirai Y, Hasumi K. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. Tumor Biol 2000; 21:375-380.
8. Bolli JA, Doering DL, Bosscher JR, Day TG Jr, Rao CV, Owens K, et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1994; 55:169-173.
9. Hatano K, Sekiya Y, Araki H, Sakai M, Togawa T, Narita Y, et al. Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1999; 45: 639-644.
10. Sharma P, Kumar R, Singh H, Jeph S, Sharma DN, Bal C, et al. Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence. Clin Nucl Med 2012; 37:649-655.
11. Sharma P, Kumar R, Singh H, Jeph S, Sharma JB, Jain SK, et al. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging. Nucl Med Commun 2012; 33: 185-190.
12. Son H, Khan SM, Rahaman J, Cameron KL, Prasad-Hayes M, Chuang L, et al. Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics 2011; 31:569-583.
13. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007; 298:2289-2295.
14. Pan L, Cheng J, Zhou M, Yao Z, Zhang Y. The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer. J Cancer Res Clin Oncol 2012; 138:239-246.
15. Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol 2011; 120:270-274.
16. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 2002; 53:353-359.
17. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer 2010; 116: 1469-1475.
18. Ryu SY, Kim MH, Choi SC, Choi CW, Lee KH. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003; 44:347-352.
19. Graves EE, Quon A, Loo BW. RT-Image: an open-source tool for investigating PET in radiation oncology. Technol Cancer Res Treat 2007; 6:111-121.
20. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 1999; 2:159-171.
21. Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, et al. Carcinoma of the cervix uteri. Int J Gynaecol Obstet 2003; 83: S41-S78.
22. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985; 3:1079-1085.
23. Sakurai H, Mitsuhashi N, Takahashi M, Akimoto T, Muramatsu H, Ishikawa H, et al. Analysis of recurrence of squamous cell carcinoma of the uterine cervix after definitive radiation therapy alone: patterns of recurrence, latent periods, and prognosis. Int J Radiat Oncol Biol Phys 2001; 50:1136-1144.
24. Sasaoka M, Fuwa N, Asano A, Matsumoto A, Katou E, Ito Y. Patterns of failure in carcinoma of the uterine cervix treated with definitive radiotherapy alone. Am J Clin Oncol 2001; 24:586-590.
25. Elst P, Ahankour F, Tjalma W. Management of recurrent cervical cancer. Review of the literature and case report. Eur J Gynaecol Oncol 2007; 28:435-441.
26. Chung HH, Nam BH, Kim JW, Kang KW, Park NH, Song YS, et al. Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer. Eur J Nucl Med Mol Imaging 2010; 37:1467-1473.
27. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 2012; 264:559-566.
28. Siva S, Herschtal A, Thomas JM, Bernshaw DM, Gill S, Hicks RJ, et al. Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer 2011; 117:3981-3988.
29. Vercellino L, Groheux D, Thoury A, Delord M, Schlageter MH, Delpech Y, et al. Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM PET/CT. Clin Nucl Med 2012; 37:1065-1068.